Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)

Usage of Vinorelbin ORAL (Navelbine® ORAL) in the Treatment of Advanced Non-small Cell Lung Cancer(NSCLC)and Advanced Breast Cancer

The purpose of this non-interventional study is to collect data on efficacy and toxicity of the use of Navelbine ORAL in daily routine in Germany (especially after availability of an 80mg capsule). The study focusses on concomitant antiemetic therapy and patient compliance.

Inclusion Criteria:

• At least 18 years old
• Male and female patients
• Advanced NSCLC (Stage III or IV) or Antracycline-resistant MBC
• Therapy with Navelbine capsules in any palliative treatment line
• Signed patient informed consent

Exclusion Criteria:

• Pregnancy and nursing
• All other exclusion criteria listed in SPC (summary of product characteristics)
• lack of signed Patient informed consent